Based on the invasive pneumococcal isolates referred to reference laboratories in Scotland in 1988-99, we identified the distribution of serotypes\groups and their antimicrobial resistance patterns in order to evaluate the coverage of polysaccharide and the new pneumococcal conjugate vaccines. A total of 5659 invasive isolates were included. Of these, 5124 (90n5%) were blood isolates, 308 (5n5 %) were CSF isolates, 143 (2n5 %) were blood and CSF and 84 (1n5 %) were other normally sterile isolates. The most prevalent 11 serotypes\groups were 14, 9, 19, 6, 23, 1, 3, 4, 7, 8 and 18, in numerical order. These accounted for 84 % of total serotypes\groups.
INTRODUCTION
Despite the availability of effective antibiotics, invasive pneumococcal disease remains a serious public health problem worldwide. Streptococcus pneumoniae is a leading cause of bacteraemia and meningitis [1, 2] particularly among the very young and elderly and being developed and evaluated [8] . In addition, conjugate pneumococcal vaccines may have a future role in protecting the elderly and adults with conditions placing them at increased risk of pneumococcal disease.
The effectiveness of polysaccharide and conjugate vaccines is dependent on the distribution of vaccine serotypes in the population being immunized [9] . Therefore, knowledge of the distribution of pneumococcal serotypes\groups within a defined population is important in developing rational vaccine policy for the future use of conjugate pneumococcal vaccines in the prevention of invasive pneumococcal disease. This paper reviews population based data on Streptococcus pneumoniae isolates identified from sterile body site specimens in Scotland during the period 1988-99 and examines the seroepidemiological characteristics of invasive pneumococcal disease.
METHODS AND MATERIALS

Background
The data for this study were obtained from Scottish Centre for Infection and Environmental Health (SCIEH) and Scottish Meningococcus and Pneumococcus Reference Laboratory (SMPRL). SCIEH serves as a national surveillance centre for monitoring infectious diseases and environmental hazards. Reports from laboratories throughout Scotland are received by SCIEH on a weekly basis. SMPRL is the national reference laboratory for pneumococcal disease. It has been established to enhance national surveillance for these diseases and has excellent links with microbiology laboratories throughout Scotland. It acts as a national centre for serotyping and antibiotic sensitivity testing of pneumococcal isolates. Laboratory records of Streptococcus pneumoniae reported to SCIEH (1988 and the pneumococcal isolates received routinely by SMPRL (1993-1998\9) from all diagnostic laboratories in Scotland have been combined in a single database.
Study data
Only invasive isolates (blood, cerebrospinal fluid (CSF) and other normally sterile sites) were included in this study. Duplicate records in SCIEH and SMPRL datasets were excluded. The Danish system of nomenclature was used for reporting pneumococcal serotypes\groups in both data bases. Isolates that had values of minimal inhibitory concentration (MIC) 0n06 µg\ml, between 0n12 and 1n0 µg\ml and 2n0 µg\ml or higher were defined as sensitive, intermediate, and high level penicillin resistance respectively. Isolates with MICs of intermediate and resistant levels were described as non-susceptible. Pneumococcal isolates that had erythromycin level of 1 µg\ml and 1 µg\ml were recorded as sensitive and resistant respectively. The MICs were determined on the receipt of organism with the use of standard agar dilution MIC method in 1992-3 and the E-test method (Cambridge Diagnostics, Cambridge UK) since 1994.
Statistical analysis
Data analysis of pneumococcal isolates, serotypes\ groups, specimen type, vaccine serotypes\groups and antimicrobial resistance were performed on the combined study dataset using SPSS version 8. 95 % confidence intervals were calculated for the coverage of vaccines in different age groups during 1993-9.
RESULTS
A total of 17 628 Streptococcus pneumoniae cases were recorded in the SCIEH and SMPRL databases over the study period. After removal of duplicate records, 10150 cases remained. Of these, only 5659 cases were from blood, CSF and other sterile site specimens and were included in the study. Of the 5659 invasive isolates, 5124 (90n5 %) were blood isolates, 308 (5n5%) were CSF isolates, 143 (2n5 %) were isolated from both blood and CSF, and 84 (1n5 %) were other sterile site isolates (Table 1) . A high proportion, 2499 (44n2 %) were from elderly 65 years old and only 661 (11n7 %) were from children 5 years old. 2601 (46 %) were from females, 2886 (51 %) from males and 172 (3 %) sex unknown were included. The median and mean age of patients was 63 and 54 years old respectively. Information on serotypes\groups was available for 1531 isolates. Of these, only 105 (6n9 %) isolates had their serotype\group reported during 1988-92. However, a high proportion, 1426 (93n1 %) isolates had their serotype\group recorded in 1993-99 due to the establishment of SMPRL in 1992\3. The distribution among the 15 Health Boards in Scotland of isolates whose serotypes\groups were determined was as follows : Greater Glasgow, 428 ; Lothian, 400 ; Lanarkshire, 235 ; Grampian, 120 ; Ayrshire and Arran, 88 ; Argyll and Clyde, 60 ; Forth 
Serotypes/groups distribution 1988/9
Most pre alent 11 serotypes\groups
The leading 11 serotypes\groups were identified among different age groups (Table 2 ). In all age groups, these serotypes\groups accounted for over 80 % of all invasive pneumococcal isolates. Overall, type 14 was the most prevalent serotype, accounting for about 10-32 % of invasive isolates. Serotype 1 was the most prevalent in the age group 5-64 years accounting for 13 % of invasive pneumococcal isolates.
Annual pattern of most pre alent serotypes\groups
The prevalence of individual serotypes\groups fluctuated from year to year of the period 1993-9 (Table  3) . This shows an increase in serotype 14 and a decline in serotype 3 in recent years.
Prevalence of vaccine-related serotypes/groups
Co erage by 23-alent and 14-alent polysaccharide accines
The current 23-valent and previous 14-valent vaccines covered 96 and 88 % of reported pneumococcal serotypes\groups isolated in all age groups in the study period. The reported coverage in individual age groups is shown in Table 4 .
Co erage by 7, 9 and 11-alent conjugate pneumococcal accines
The 7-valent conjugate vaccine includes serotypes 4, 6B, 9V, 14, 18C, 19F and 23F [8] . Serotypes 1 and 5 are added in the 9-valent vaccine and 1, 3, 5, 7F in the 11-valent vaccine [10] . These 7, 9 and 11-valent conjugate vaccines covered 61, 68 and 80 % of reported pneumococcal serotypes\groups isolated in all groups respectively. Coverage was substantially higher in the 2 years than in older age groups (Table 4) .
Co erage of in asi e serotypes\groups with 23-alent polysaccharide and the 7-, 9-and 11-alent conjugate accines : annual fluctuation o er the period 1993-9
The 23-valent polysaccharide vaccine covered 90 % of invasive isolates in all ages. However, the annual coverage of the 7, 9 and 11-valent conjugate vaccine showed substantial annual variation. Coverage was 59-97, 64-97 and 77-100 % for 7, 9 and 11-valent conjugate vaccine in 2 years age group, 42-69, 47-75 and 57-88 % for 7, 9 and 11-valent conjugate vaccine in 65 years age group and 53-73, 60-76 and 75-82 % for 7, 9 and 11-valent conjugate vaccine for all ages (Table 5) . 
Most prevalent serotypes/groups not included in the new 11-valent conjugate vaccine
Serotypes\group 8, 11, 12 and 22 were the most common nor-vaccine serotypes\groups, accounting for 178 (12 %) of invasive isolates in all ages (Table 6) . A higher proportion of them was recorded in those 5 years of age.
Penicillin/erythromycin susceptibility
The distribution of serotypes\groups that were penicillin and erythromycin susceptible and non-susceptible is shown in 
Vaccine coverage of antibiotic susceptible and nonsusceptible invasive pneumococcal isolates
The 23-and 14-valent polysaccharide vaccine provided 97-100 % and 86-98 % coverage of all penicillin susceptible and non-susceptible isolates respectively. The conjugate pneumococcal vaccines covered 58-79 % and 94-100 % of susceptible and nonsusceptible isolates (Table 8) . A similar pattern was noted for erythromycin sensitive and resistant isolates (Table 8) .
DISCUSSION
There are very few contemporary data on the distribution of invasive pneumococcal serotypes\ groups in the UK. This study reports seroepidemiological characteristics of invasive pneumococcal isolates referred to reference laboratories in Scotland over the period 1988-99. The 7, 9 and 11-valent conjugate vaccines are now undergoing clinical trials in both developed and developing countries [8] .
Earlier data on safety and immunogenicity of conjugate vaccines are encouraging among infants, and young children, [11] [12] [13] [14] [15] [16] adults, [17, 18] and those with medical conditions which compromise immune function [19] [20] [21] [22] [23] [24] . The result of the first large-scale clinical trial from Southern California showed that the 7-valent conjugate vaccines had 100 % efficacy in prevention of invasive pneumococcal infections in infants and children caused by the vaccine serotypes\ groups [25] . This suggests that the 7-valent conjugate vaccine may soon be licensed for use in infants and children in developed countries. It has been proposed that pneumococcal conjugate vaccines may also have an important role in preventing pneumococcal disease in the elderly [26] .
Therefore, an understanding of the serotype distribution of pneumococcal isolates will be crucial in developing appropriate immunization policy for different age groups in Scotland. This study reports on the coverage of serotypes\groups in the current polysaccharide and the new conjugate pneumococcal vaccines in Scotland.
Serotypes/groups distributions
We found that the most prevalent serotypes (14, 9, 19, 6, 23, 1, 3, 4, 7, 8 and 18) accounted for over 82-94 % of total serotypes\groups in all age groups. Inclusion of these serotypes\groups in the new 11-valent conjugate vaccine will therefore cover 80 % of invasive pneumococcal serotypes\groups in children, adults and the elderly. This is similar to previous findings from the US [27, 28] , Europe [29] [30] [31] , New Zealand [32] and Australia [33] . In contrast, data from Africa and Asia showed that serotypes 1 and 5 were the predominant invasive isolates [9, 34] .
The major serotypes\groups in different age groups included serotypes\groups 14, 6, 19, 23 and 9 in 2 years, 14, 6, 23, 19 and 18 in 5 years, 1, 9, 14, 7 and 4 in 5-64 years old and 14, 19, 3, 9 and 23 in 65 years old. In common with some other studies, our data indicate that type 14 was the most common infectious serotype in all age groups [9, 35] .
Among the age group 5-64 years, serotype 1 was the main cause of invasive disease, accounting for about 13 % of cases. Earlier reports from US have observed that serogroup 12 is the most frequent cause of bacteraemia in patients with pneumonia [36] and associated with outbreaks in both children [37] and adults [38] . In addition, surveillance data from the US and Europe indicate that a shift of serotypes distribution can occur over time [39] . Types 1-3 were the most prevalent isolates in bacteraemic cases at the beginning of the century, accounting for c. 70 % of Invasive pneumococcal isolates invasive isolates [40, 41] . However, since 1979, these isolates have been very much less common ( 5%) [42] , and serotypes 6, 14, 18 and 23 are more frequently isolated in the US [43] and Europe [30, 31, 44] . This suggests that continued surveillance systems are essential to monitor the stability of pneumococcal serotypes\groups distribution in Scotland. Review of serotype data from sterile site specimens from 16 countries showed that serotypes\groups 14, 6 and 19 were consistently found in all geographic locations [9] . However, the important invasive serotypes in children 5 years of age varied, with serotype 18 most prevalent in developed countries, type 23 in Europe and serotypes 1 and 5 in developing countries. These differences in serotypes\groups distribution impose a challenge for designing a conjugate vaccine with appropriate serotypes distribution for all locations.
The 23-and 14-valent pneumococcal polysaccharide vaccines
The increase in antibiotic resistant pneumococcal [45] and the high burden of invasive pneumococcal disease among high-risk groups has been documented consistently [10] . Pneumococcal polysaccharide vaccines have been estimated by case-control and indirect cohort studies, to be 50-80 % effective in reducing invasive pneumococcal disease in the elderly and in adults with chronic medical conditions [46] . We have found that the 23-valent and (previous) 14-valent polysaccharide vaccines covered 97 % and 83 % respectively of invasive isolates. This is similar to published data from other parts of UK, Europe and North America ; 91-97 % in England and Wales, and Scotland [35, 47, 48] , 89-97 % in Sweden [49] , 85 % in the US [5, 27] , 90 % in Canada [50] , 95 % in Finland [31] and 92 % in Denmark [30] for older children and adults. Limited data are available on serotypes\groups distribution in Asia and Africa where mortality rates from pneumococcal disease are high. The available data from Asian countries show a large variation in the proportion of invasive pneumococcal isolates covered by the 23-valent vaccine : 75 % in Bangladesh, 70n5 % in Korea [51] and 62n9 % in Taiwan [52] .
Conjugate vaccines
Conjugate pneumococcal vaccines are undergoing phase I, II, and III clinical trials in the US, South Africa, Israel, Gambia, Finland and Philippines [8, 53] . Based on serological data, pneumococcal conjugate vaccines appear to produce a more immunogenic response in infants, the elderly, and immunocompromised individuals than pneumococcal polysaccharide vaccines [26] . In addition, findings from South Africa [54] Gambia [55] and Israel [56] reveal that conjugate vaccines reduce nasopharyngeal carriage of vaccine serotypes. Therefore, it may be possible to achieve herd immunity by widespread use of conjugate vaccines in the future. Data from the US suggest that the serotypes included in the current 7-valent conjugate vaccine could prevent 86 % and 83 % of pneumococcal bacteraemia and meningitis in children 6 years old [43] . A previous survey in England and Wales [4, 48] noted that about 73 % of isolates found in children 2 years old were included in the 9-valent conjugate vaccines. We found a higher coverage of 90 % with the 11-valent conjugate vaccine and 80 % with the 7-9 valent conjugate vaccines for children 2 years of age. The 11-valent vaccine also covers serogroups 3, 19 and 23 that were mainly responsible for otitis media in US, Canadian and European children [57] . Therefore, it is unlikely that pneumococcal conjugate vaccines for children need to include 11 serotypes. However, a substantially lower coverage was observed, (about 50-57 % with 7-valent, 62-63 % with 9-valent and 75-76 % with 11-valent conjugate vaccines) in those above 5 years (including elderly 65 years). In addition coverage in this age group fluctuated from year to year, over the period 1993-9.
Serotypes\groups 8, 11, 12 and 22 were the most common invasive isolates not present in the 11-valent vaccine, accounting for 15n6 and 12n4 % of isolates in 5-64 years old and 65 years old respectively. Including these serotypes\groups in the 11-valent could increase the vaccine coverage to 80 % of invasive isolates in these age groups. However, a larger number of serotypes attached to a carrier protein could lead to poorer immunogenicity and possibly promote serious local reactions [58] . Further research is required on this issue. Furthermore, concerns about the replacement of vaccine serotypes by serotypes not in the vaccine have been expressed [55] and are now under investigation [54] .
Drug susceptible pneumococcal isolates
Pneumococcal isolates that are resistant to penicillin and other antimicrobial drugs have been detected on all continents [59, 60] . Serogroups 6, 19 and 23 have been most associated with drug resistance [59, 61] .
In the present study, serotypes\groups 6, 14, 19 and 23 were the most commonly associated with intermediate resistance and serotype 14 with penicillin and erythromycin resistant isolates. A previous survey from England and Wales identified similar serotypes\ groups (23F, 6B, 19A, 19C, 19F and 23F) associated with intermediate or high penicillin resistance. Resistancetoerythromycin wasassociatedwith serotypes\ groups (3, 5, 9, 14, 19 and 22) in 1990 and with serotypes\groups (3, 6, 14, 15, 19 and 23) in 1995 [48] . Other UK studies also indicated that type 23, 9 and 6 were most commonly associated with penicillin resistance [62] [63] [64] .
The commonest serotypes\groups associated with penicillin resistance in other countries included 9, 23 in Canada [50, 65] , 6, 14, 19 and 23 in South Africa, Spain and Hungary [45] and 6B, 9V, 14, 19F and 23F in the US [66] . In general, these data suggest that the main serotypes patterns associated with lack of susceptibility to penicillin and erythromycin are similar in most geographical areas. However, recently, type 15 in Spain and type 10 [67] and 16 and 13 in Kenya [68, 69] have been found to be associated with penicillin resistance.
Our data show that the 23-valent vaccine covers 99 % of invasive isolates which were found to be non-susceptible to penicillin or resistant to erythromycin. The 11-valent conjugate vaccine covered 78 %, and 7-and 9-valent covered 56 % of nonsusceptible and resistant invasive isolates for both drugs. Therefore, a greater use of 23-valent or the new 11-valent conjugate vaccine could possibly reduce the majority of penicillin non-susceptible and erythromycin resistant invasive pneumococcal isolates.
The data presented in this study should be helpful in predicting the potential impact of pneumococcal vaccines on invasive pneumococcal disease. There is a need for complementary data on isolates associated with important non-invasive pneumococcal disease such as otitis media in order to inform future policies on the prevention of pneumococcal disease in Scotland.
